Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

WILMINGTON, North Carolina, June 3, 2010 - Intercell AG has retained Inclinix, Inc., to recruit volunteers for their
Phase III clinical trial of an investigational Travelers' Diarrhea (TD)
vaccine system. The TD vaccine is in the form of a skin patch - a novel
method for delivering a vaccine that is especially innovative because it is
needle-free.

This year, approximately 55 million international travelers will visit
countries where bacteria that cause TD are endemic, particularly Africa, Asia
and Latin America, with nearly 20 million of those travelers developing TD.
The effects extend beyond the acute symptoms of the disease; between 10 and
30 percent of those who develop TD will develop the chronic symptoms of
irritable bowel syndrome.

Inclinix, a Wilmington, North Carolina, USA-based clinical trial
enrolment solutions provider, will utilize its innovative recruitment tactics
to drive the enrolment of 1800 volunteers in Western Europe beginning in
April 2009. Current departure cities where clinics are conducting the TREK
Study are Belfast, Glasgow, London, Manchester, Birmingham and Reading in the
UK and Berlin, Munich, Potsdam and Hamburg in Germany.

"We are pleased that Intercell AG has chosen Inclinix as their partner
for the Trek Study," says J. Tobin Geatz, President and CEO, Inclinix. "We
look forward to the opportunity to contribute to the development of this
novel vaccine that has such potential to make a truly global medical impact."

Travel to Guatemala and the surrounding countries increased 13% in 2007,
while Mexico was cited as the 10th most visited country in the world with
almost 20 million arrivals in-country. These findings coincide with
Intercell's interest in reaching large numbers of travelers interested in
experiencing Guatemala or Mexico.

TREK travel specialists will be in contact with volunteers through a
variety of communication methods, building excitement and providing helpful
study and travel information. The TREK research study web site
www.trekstudy.com, allows interested participants to register to
receive continuously updated information on topics such as travel
destinations, group travel and study compensation. Volunteers will receive
compensation for participation, along with pre-paid mobile phones and welcome
kits with useful travel tools.

About the TREK Study

Based on the Phase II safety and efficacy data, this pivotal Phase III
trial will follow approximately 1800 healthy volunteers age 18+ to Mexico and
Guatemala. Volunteers will receive two doses of the TD vaccine or a placebo,
two weeks apart, with the last dose at least seven days prior to travel.
Volunteers will then be surveyed via diary and visits for 17 days. The
primary purpose of this trial is to evaluate the efficacy of the TD vaccine
system.

The successful Phase II study followed 170 healthy travelers aged 18-64
to Mexico and Guatemala. The study found that of the 59 individuals who
received the vaccine, only three suffered from moderate or severe diarrhea,
while 23 of the 111 receiving a placebo suffered from moderate or severe
diarrhea, a 75 percent reduction (p=0.007). No vaccine-related serious
adverse events were reported.

About Intercell AG

Intercell USA, Inc. is a subsidiary of Intercell AG. Intercell AG is a
growing biotechnology company which focuses on the design and development of
novel vaccines for the prevention and treatment of infectious diseases with
substantial unmet medical need. The Company's technology platforms include an
antigen-discovery system, adjuvants and a novel patch-based delivery system
(Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies,
Intercell has strategic partnerships with a number of global pharmaceutical
companies, including GSK, Novartis, Merck & Co., Inc., Sanofi Pasteur, and
Wyeth.

For more information on Intercell, please visit: www.intercell.com

About Inclinix, Inc.

Inclinix, Inc., a global clinical trial solutions provider specializing
in customized Phase I-IV clinical trial enrolment solutions. Comprehensive
enrolment solutions include site recruitment, patient recruitment, clinical
and medical marketing, monitoring, and patient compliance and education.
Inclinix corporate headquarters is located in Wilmington, North Carolina USA,
with additional offices in Annapolis, Maryland USA, and Gothenburg, Sweden.
www.inclinix.com

Kristin Sacre, +1-910-332-2682, ksacre at inclinix.com